SCHEMBL4813787

SCHEMBL4813787

CCn1cc(Cc2ccccc2-c2cc3c(cc2C(=O)O)OCO3)c2ccc(C(=N)N)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
HPGD P15428 1/20 0.46
APEX1 P27695 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
RXFP1 Q9HBX9 1/20 0.37
EDNRA P25101 6/20 0.37
EDNRB P24530 5/20 0.37
SLC22A12 Q96S37 1/20 0.36
TP53 P04637 3/20 0.35
MAPT P10636 3/20 0.34
ATM Q13315 1/20 0.34
TSHR P16473 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811451 0.87 SLC22A12 (0.41) KDM4EALDH1A1CYP1A2CYP2D6HPGD
SCHEMBL4815014 0.85 SLC22A12 (0.40) KDM4EALDH1A1CYP1A2CYP2D6HPGD
SCHEMBL4814925 0.85 PLA2G4A (0.40) KDM4EALDH1A1SLC22A12
SCHEMBL4808748 0.83 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10SLC22A12
SCHEMBL4814585 0.81 SLC22A12 (0.48) SLC22A12PDE4APDE4BPDE4CPDE4D
SCHEMBL4815488 0.80 SLC22A12 (0.42) SLC22A12
SCHEMBL4813962 0.79 KMT2A (0.38) ALDH1A1SLC22A12MAPTTSHR
SCHEMBL4809607 0.79 SLC22A12 (0.37) SLC22A12
SCHEMBL4863979 0.79 SLC22A12 (0.36) SLC22A12PDE4APDE4BPDE4CPDE4D
SCHEMBL4812974 0.79 TDP1 (0.40) KDM4EALDH1A1HSD17B10TDP1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US claimed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent F12, F11, F2 KDM4E 316/4885ALDH1A1 3830/4885CYP1A2 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.